AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06202040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Rectus Sheath Block (RSB) will be performed.
Description: When the patient is in the supine position, the ultrasound (USG) linear probe is held in the transverse plane at the level just above the umbilicus, where the posterior rectus sheath is best visualized. Using the in-plane technique with a 100mm 22 G needle under USG guidance, the drug prepared will be administered between the rectus muscle and the posterior rectus sheath. For this block, a volume of 20cc will be prepared, consisting of 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral Rectus Sheath Block (RSB) will be applied with a total volume of 20cc, 10cc to each side.
Study NCT04934657 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04766411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control trial
Description: Participants will not perform any sprint training protocol
Study NCT06171828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head-Mounted Display (HMD) to communicate with a supervisor remotely
Description: Participants in the experimental group are oriented on using the education platform and communicating with the supervisor through an HMD for about 5 minutes. They then perform and save their ultrasound imaging. If they require assistance, they request help verbally through the HMD's communication system. The supervisor remotely observes and immediately assists upon request, utilizing the HMD and a 360-degree camera.
Study NCT05162313 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: confirmation of endotracheal tube positioning
Description: After performing the tube insertion by direct laryngoscopy, videolaringoscopy or fiberoptic technique, the attending neonatologist will connect both the colorimetric capnometer and the proximal flow-sensor to the tracheal tube. If the flow sensor is not proximal but incorporated into the mechanical ventilator, the care provider will connect the capnometer only. During the procedure, the information given by the capnometer will be evaluated by the care provider performing the intubation, while the flow sensor information will be monitored only by a study investigator, who will not reveal any details to the care provider. In particular, the yellow color change by the capnometer and the presence of exhalation flow curves on the ventilator screen will be considered as confirmation of correct tracheal tube positioning, respectively.
Study NCT05987956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib - Usual
Description: Usual Alectinib Chemotherapy (NDC...01)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily
Study NCT05987956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib - Study
Description: Study Alectinib Chemotherapy (NDC...86)~- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily
Study NCT06095609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization plus chest physiotherapy
Description: Early mobilization:early mobilization has been confirmed its positive effectiveness on cutting down the MV use days and mortality rate, attenuating the side effect such as muscle strength loss and functional activity dysfunction resulting from ICU acquired weakness among the patients with mechanical ventilation.~Chest physiotherapy:a common technique to reduce the respiratory complications in ICU, has been proved certain positive influence on airway clearance and hospital lengths of stay.
Study NCT04707300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human T Lymphoid Progenitor (HTLP) injection
Description: The HTLP cell suspension will be injected intravenously at the time of UCB HSCT on D0
Study NCT06388603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioactive Glass
Description: Bonalive Granules and Bonalive Putty will be used (according to their IFU and CE certification) to fill the bone void after the debridment of infected tissue as they have osteoconductive and osteostimulative properties that allow bone rigeneration. Moreover, Bonalive Granules also present some bacteria growth inhibiting properties to combact bone infection propoer of Ostemyelitis.
Study NCT06388603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The investigators are left free to proceed according to the normal standar procedure they normally use. The procedures can vary according to investigator judgment also depending on the state of Osteomylitis.
Study NCT06168487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Patients will be given telmisartan alone or with standard of care chemotherapy.
Study NCT06168487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Regimen
Description: Standard of Care Regimen
Study NCT06140095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: See arm description
Study NCT05111977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrant capsule
Description: A capsule delivering mechanical vibrations
Study NCT05111977 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vibrant capsule
Description: A capsule delivering mechanical vibrations
Study NCT04540289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT)
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure
Study NCT05180175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Top down treatment if patient at high risk
Description: Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
Study NCT06264856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoscopic sputum suction
Description: Bronchoscopy is a medical procedure in which a flexible tube called a bronchoscope is passed through the mouth or nose and into the lungs. Bronchoscopic suction is a technique used during bronchoscopy to remove secretions, mucus, or foreign objects from the airways.~The bronchoscope is equipped with a suction port and a suction channel that allows the doctor to remove fluids or other material from the airways. The suction port is connected to a vacuum source, and the suction channel runs through the bronchoscope and terminates at the tip of the instrument.
Study NCT06264856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: negative pressure aspiration suction
Description: The procedure involves inserting a catheter into the airway and applying negative pressure to the catheter to suction out the secretions or fluids. The patient could receive sputum suction as medical routine (every 2-4 hrs) if needed.
Study NCT05216341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.
Study NCT04540289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure
Study NCT04540289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Description: An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed.
Study NCT06255951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.
Study NCT06255951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.
Study NCT04641611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicaval cannulation
Description: Cannulation of SVC and IVC through right atrium in patients undergoing CABG. with snares applied
Study NCT04641611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cavoatrial cannulation
Description: Cannulating the right atrium and Inferior vena cava with a 2-stage cannula
Study NCT04879004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine injection
Description: Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.
Study NCT04879004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.
Study NCT05615506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction Diathermy Adenoidectomy
Description: suction diathermy adenoidectomy
Study NCT05763823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Letermovir 240 mg or 480 mg oral tablets or IV once daily dose
Study NCT05518968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: 8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
Study NCT06360120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
Study NCT06360120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
Study NCT05216341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OLP-1002
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.
Study NCT04929444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training on vertigo
Description: Online training on vertigo management in primary care with a face-to-face session.~On the one hand, the course will contain theoretical content and clinical cases will be used as the methodology of the course, with feedback paths for each correct or incorrect answer from the students and videos recorded expressly for the course. In addition, there will be a face-to-face session where all participants must perform the diagnostic and therapeutic maneuvers proposed in the course, to evaluate the use of the training and also to standardize the way of doing them for the study
Study NCT05804734 — intervention group
Intervention type: DRUG
Intervention: Vitamin K Antagonist - Drug
Description: Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~* For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~* For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment.
Study NCT04464148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 250 mg
Description: Pregnenolone 250 mg capsule BID (500 mg QD total)
Study NCT04464148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 400 mg
Description: Pregnenolone 400 mg capsule BID (800 mg QD total)
Study NCT05228834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor Only Product in Oral Dose Form
Description: During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
Study NCT05228834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
Study NCT05336149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using whole-tooth dentin graft
Description: Minimally-traumatic extraction of non-restorable teeth then grafting with whole-tooth dentin graft
Study NCT05336149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using particulate dentin graft
Description: Minimally-traumatic extraction of non-restorable teeth then grafting with particulate dentin graft
Study NCT04680975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: 10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks
Study NCT05704790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Compensatory Training
Description: The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
Study NCT06039358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine.
Description: Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
Study NCT06039358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellulose.
Description: Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
Study NCT04090619 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT06172075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (Black Woman)
Description: A brief social contact-based video. The video presented a young Black woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Black woman with depression and raising themes of recovery and hope.
Study NCT06172075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (Latinx Woman)
Description: A brief social contact-based video. The video presented a young Latinx woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Latinx woman with depression and raising themes of recovery and hope.
Study NCT06172075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (White Woman)
Description: A brief social contact-based video. The video presented a young White woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a White woman with depression and raising themes of recovery and hope.
Study NCT06172075 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vignette Control
Description: A brief vignette control condition with a script about a young woman who describes her struggles with depression and raises themes of recovery and hope.
Study NCT06471075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Pain Management
Description: The mindfulness intervention will involve a 2-minute introduction to mindfulness as a technique for pain management followed by a 5-minute, audio-guided, mindful breathing practice.
Study NCT06471075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Psychoeducation
Description: In the pain psychoeducation intervention, participants will be provided timematched information about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
Study NCT06584500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling will be performed on the pelvitrochanteric musculature, targeting those muscles where the patient reports mechanical hyperalgesia points upon palpation that reproduce familiar and recognizable pain. No more than 3 different muscles will be treated, and no more than 2 needles will be used per muscle to reduce irritability. The Gluteus Medius muscle will be needled in all patients, and the Gluteus Minimus, Tensor Fasciae Latae (TFL), Piriformis, and obturator muscles will also be examined.~Dry needling will be performed using monofilament needles of different sizes, 0.30mm x 7.5mm, 6mm, and 4mm (AGUPUNT, APS®), depending on the muscle being treated.\&#34;~During the dry needling procedure, an attempt will be made to provoke a local twitch response (LTR). Once achieved, the needle will be manipulated with rapid in-and-out movements in different directions until 4 to 6 LTRs are obtained, or if the participant verbally requests the intervention to stop.
Study NCT06584500 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: The intervention protocol for sham dry needlig will be just as to the real dry needling procedure, but instead of inserting the needle into the muscle, the needle is manipulated to touch the skin without penetrating it. This may involve the use of retractable needles or simply making contact with the skin
Study NCT06583369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liangxue ointment（Traditional Chinese Ointment）
Description: The main ingredients of Liangxue Ointment include: Lithospermum sibiricum, Sanguisorba Sanguis, Rehmannia glutinosa, Gardenia, rhubarb, skullcap, borneol, dragon's blood, olibanum and myrrh.~Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
Study NCT06583369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urea cream
Description: Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
Study NCT04752358 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified ADP-A2M4CD8 cells
Description: Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
Study NCT06257173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The experimental group will receive 2 hours of patient safety training with a peer educator.
Study NCT05290389 — intervention group
Intervention type: OTHER
Intervention: SMART AMI APPLICATION
Description: SMART AMI allows real-time sharing and review of patient history and ECG between Emergency Department physicians and Interventional Cardiologists to allow for immediate decision-making regarding the need for percutaneous coronary intervention.~Participant physicians will use a smartphone application to communicate, transmit the ECG, and activate the STEMI team. This application enables calling and transmission of up to three images of ECGs, which can be reviewed immediately by the Interventional Cardiologist when communicating with the referring physician.
Study NCT05989854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8 week exercise intervention, 3x/wk
Study NCT06100393 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Investigational Pre-Processing Algorithm (Sub A)
Description: The algorithms act upon the digital audio signal received by the microphones and other sensors to enhance speech and attenuate noise prior to encoding the signal for delivery to a cochlear implant via the specified system.
Study NCT06100393 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cochlear Limited standard-of-care pre-processing algorithms
Description: Automatic Gain Control, SNR-NR, Forward Focus
Study NCT06100393 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Investigational Pre-Processing Algorithm (Sub B)
Description: Spatial Automation profile
Study NCT05854342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bicarbonate-calcium water
Description: water with high content of bicarbonate and calcium, low sodium